Listen to ASX-listed Noxopharm CEO Dr Graham Kelly talk to Matt Birney on the Bulls N’ Bears report about how Noxopharm has protected its potentially lucrative looking biotechnology that it says aims to boost the effectiveness of existing anti-cancer treatments.
